CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.

Handel Citius Pharmaceuticals, Inc. - CTXR CFD

1.2859
4.03%
0.0382
Lav: 1.2261
Høj: 1.286
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.0382
Long position, gebyr natten over

Long position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.025457%
Short position, gebyr natten over

Short position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
0.003235%
Gebyr natten over, tid 21:00 (UTC)
Min. handlet mængde 1
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Citius Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

Nøglestatistikker
Tidligere luk* 1.2361
Åben* 1.2461
1-Års Ændring* 41.6%
Dagens Spænd* 1.2261 - 1.286
52-Ugers Spænd 0.77-1.71
Gennemsnitlig Volumen (10 dage) 1.19M
Gennemsnitlig Volumen (3 måneder) 30.29M
Market Cap 196.98M
P/E-forhold -100.00K
Udestående aktier 158.86M
Omsætning N/A
EPS -0.21
Dividend (Udbytte %) N/A
Beta 1.39
Næste indtjeningsopgørelse Aug 9, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Jun 2, 2023 1.2859 0.0398 3.19% 1.2461 1.3059 1.2162
Jun 1, 2023 1.2361 0.0897 7.82% 1.1464 1.2959 1.1364
May 31, 2023 1.1364 0.0399 3.64% 1.0965 1.1464 1.0965
May 30, 2023 1.0965 -0.0100 -0.90% 1.1065 1.1364 1.0965
May 26, 2023 1.1065 0.0299 2.78% 1.0766 1.1165 1.0766
May 25, 2023 1.0766 -0.0498 -4.42% 1.1264 1.1264 1.0666
May 24, 2023 1.1065 0.0200 1.84% 1.0865 1.1364 1.0666
May 23, 2023 1.0965 -0.0299 -2.65% 1.1264 1.1464 1.0666
May 22, 2023 1.1264 -0.0399 -3.42% 1.1663 1.1763 1.1264
May 19, 2023 1.1663 0.0199 1.74% 1.1464 1.1763 1.1264
May 18, 2023 1.1165 0.0100 0.90% 1.1065 1.1564 1.0866
May 17, 2023 1.0866 -0.1694 -13.49% 1.2560 1.2561 1.0467
May 16, 2023 1.2461 0.0000 0.00% 1.2461 1.2660 1.2261
May 15, 2023 1.2660 -0.1296 -9.29% 1.3956 1.4056 1.2261
May 12, 2023 1.3956 0.0498 3.70% 1.3458 1.4355 1.2860
May 11, 2023 1.2959 0.0199 1.56% 1.2760 1.4355 1.2760
May 10, 2023 1.2461 0.0100 0.81% 1.2361 1.2860 1.1962
May 9, 2023 1.2261 -0.0399 -3.15% 1.2660 1.2760 1.2261
May 8, 2023 1.2660 -0.0100 -0.78% 1.2760 1.2959 1.2461
May 5, 2023 1.2660 0.0000 0.00% 1.2660 1.2959 1.2361

Citius Pharmaceuticals, Inc. Events

Tid (UTC) (UTC) Land Begivenhed
Wednesday, August 9, 2023

Tid (UTC) (UTC)

10:59

Land

US

Begivenhed

Q3 2023 Citius Pharmaceuticals Inc Earnings Release
Q3 2023 Citius Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Se alle begivenheder
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Total omsætning 0 0 0 0 0
Omsætning 0 0 0 0 0
Totale Driftsudgifter 33.3161 23.3653 17.7107 15.5984 13.3391
Salgs/Generelle/Admin. Udgifter, Total 15.6606 11.2914 8.89788 7.00146 7.22622
Forskning & Udvikling 17.6555 12.2405 8.81281 8.5969 6.56293
Driftsindtægter -33.3161 -23.3653 -17.7107 -15.5984 -13.3391
Renteindkomst (Udgift), Netto Ikke-Drift 0.2514 0.25099 0.0524 0.03622 -0.01584
Netto Indkomst Før Skat -33.0647 -23.0544 -17.5481 -15.5621 -12.5366
Netto Indkomst Efter Skat -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Netto Indkomst Før Ekstra Ting -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Netto Indkomst -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -33.6407 -24.5053 -17.5481 -15.5621 -12.5366
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -33.6407 -24.5053 -17.5481 -15.5621 -12.5366
Fortyndet Netto Indkomst -33.6407 -24.5053 -17.5481 -15.5621 -12.5366
Fortyndet Vægtet Gennemsnit Aktier 146.082 108.599 39.1652 20.1618 10.7319
Fortyndet EPS Uden Ekstraordinære Ting -0.23029 -0.22565 -0.44805 -0.77186 -1.16817
Fortyndet Normaliseret EPS -0.23029 -0.22718 -0.44805 -0.77186 -1.2101
Usædvanlig Udgift (Indkomst) 0 -0.16656 0 -0.45
Andre, Netto 0 0.05992 0.11021 0 0.81834
Total Adjustments to Net Income 0 -1.45088
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total omsætning 0 0 0 0 0
Omsætning 0 0 0 0 0
Totale Driftsudgifter 10.6853 3.66419 7.54957 8.91665 7.59063
Salgs/Generelle/Admin. Udgifter, Total 5.95845 3.80437 3.69234 4.02846 4.13842
Forskning & Udvikling 4.72686 3.44552 3.85723 4.88819 3.45221
Driftsindtægter -10.6853 -3.66419 -7.54957 -8.91665 -7.59063
Renteindkomst (Udgift), Netto Ikke-Drift 0.30328 0.21455 0.13483 0.05302 0.02957
Andre, Netto 0 0
Netto Indkomst Før Skat -10.382 -3.44965 -7.41474 -8.86363 -7.56105
Netto Indkomst Efter Skat -10.526 -3.59365 -7.99074 -8.86363 -7.56105
Netto Indkomst Før Ekstra Ting -10.526 -3.59365 -7.99074 -8.86363 -7.56105
Netto Indkomst -10.526 -3.59365 -7.99074 -8.86363 -7.56105
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -10.526 -3.59365 -7.99074 -8.86363 -7.56105
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -10.526 -3.59365 -7.99074 -8.86363 -7.56105
Fortyndet Netto Indkomst -10.526 -3.59365 -7.99074 -8.86363 -7.56105
Fortyndet Vægtet Gennemsnit Aktier 146.252 146.211 146.146 146.13 146.042
Fortyndet EPS Uden Ekstraordinære Ting -0.07197 -0.02458 -0.05468 -0.06066 -0.05177
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Fortyndet Normaliseret EPS -0.07197 -0.04052 -0.05468 -0.06066 -0.05177
Total Adjustments to Net Income 0 0
Usædvanlig Udgift (Indkomst) 0 -3.58569 0
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Totale Nuværende Aktiver 44.5643 72.8143 13.982 7.94192 10.0601
Likvider og Kortsigtede Investeringer 41.7117 70.073 13.8597 7.8938 9.184
Likvider & Lignende 41.7117 70.073 13.8597 7.8938 9.184
Prepaid Expenses 2.85258 2.7414 0.12224 0.04811 0.05773
Total Assets 113.999 142.429 43.7737 36.7464 31.0505
Property/Plant/Equipment, Total - Net 0.65017 0.82985 0.98778 0.00059 0.00148
Property/Plant/Equipment, Total - Gross
Accumulated Depreciation, Total
Goodwill, Net 9.3468 9.3468 9.3468 9.3468 1.5868
Intangibles, Net 59.4 59.4 19.4 19.4 19.4
Other Long Term Assets, Total 0.03806 0.03806 0.05709 0.05709 0.00217
Total Current Liabilities 4.53001 3.98229 4.09713 4.60772 3.18484
Accounts Payable 1.16538 1.2771 1.85624 2.71354 1.57344
Accrued Expenses 3.36463 2.7052 2.06793 1.72121 1.43843
Notes Payable/Short Term Debt 0 0 0.17297 0.17297 0.17297
Other Current Liabilities, Total 0
Total Liabilities 11.1734 10.2467 10.103 9.59352 3.18484
Total Long Term Debt 0 0 0.16458 0 0
Total Equity 102.826 132.182 33.6707 27.1529 27.8657
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.14621 0.14598 0.05558 0.02893 0.0162
Additional Paid-In Capital 232.368 228.084 104.209 80.1697 68.1073
Retained Earnings (Accumulated Deficit) -129.688 -96.0478 -70.5939 -53.0458 -40.2578
Total Liabilities & Shareholders’ Equity 113.999 142.429 43.7737 36.7464 31.0505
Total Common Shares Outstanding 146.211 145.979 55.577 28.9305 16.1988
Totale Tilgodehavender, Netto 0.81834
Long Term Debt 0 0.16458 0
Deferred Income Tax 5.5618 4.9858 4.9858 4.9858
Other Liabilities, Total 0.48125 0.67823 0.85547
Minority Interest 0.60038 0.60038
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Totale Nuværende Aktiver 34.9011 42.3174 44.5643 50.8345 58.2593
Likvider og Kortsigtede Investeringer 29.0655 36.8872 41.7117 48.0442 55.7562
Likvider & Lignende 29.0655 36.8872 41.7117 48.0442 55.7562
Prepaid Expenses 5.8356 5.43013 2.85258 2.79032 2.50311
Total Assets 104.241 111.705 113.999 120.316 127.786
Property/Plant/Equipment, Total - Net 0.55484 0.60299 0.65017 0.69642 0.74177
Goodwill, Net 9.3468 9.3468 9.3468 9.3468 9.3468
Intangibles, Net 59.4 59.4 59.4 59.4 59.4
Other Long Term Assets, Total 0.03806 0.03806 0.03806 0.03806 0.03806
Total Current Liabilities 6.20968 4.53717 4.53001 4.46112 4.02192
Accounts Payable 2.72559 1.53758 1.16538 1.69052 1.70513
Accrued Expenses 3.48408 2.99959 3.36463 2.7706 2.3168
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 13.0347 11.2719 11.1734 10.5802 10.1904
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Deferred Income Tax 5.8498 5.7058 5.5618 4.9858 4.9858
Minority Interest 0.60038 0.60038 0.60038 0.60038 0.60038
Other Liabilities, Total 0.37483 0.42857 0.48125 0.53288 0.5823
Total Equity 91.2061 100.433 102.826 109.736 117.596
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.14636 0.14621 0.14621 0.14613 0.14613
Additional Paid-In Capital 234.868 233.569 232.368 231.287 230.284
Retained Earnings (Accumulated Deficit) -143.808 -133.282 -129.688 -121.698 -112.834
Total Liabilities & Shareholders’ Equity 104.241 111.705 113.999 120.316 127.786
Total Common Shares Outstanding 146.358 146.211 146.211 146.13 146.13
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Netto indkomst/Startlinje -33.6407 -23.0544 -17.5481 -15.5621 -12.5366
Likvider Fra Driftsaktiviteter -28.3613 -24.2504 -16.9307 -12.4377 -11.3181
Likvider Fra Driftsaktiviteter 0.00292 0.00149 0.00084 0.00089 0.00175
Ikke-Likvide Ting 4.46091 1.5198 1.48355 0.92758 0.7069
Cash Taxes Paid
Likvid Rente Betalt 0 0.00019
Ændringer i Driftskapital 0.23956 -2.71727 -0.86697 2.19592 0.50985
Likvider fra Investeringsaktiviteter 0 -40.0069 -0.00183 0 0
Andre Investerings-Cash-Flow-Ting, Total 0
Likvider fra Financieringsaktiviteter 0 120.471 22.8984 11.1475 17.298
Financiering af Cash-Flow-Ting 0 18.4504 0 0
Udstedelse (Pensionering) af Gæld, Netto 0 -0.17297 0.16458 0 0
Netto Ændring i Likviditet -28.3613 56.2132 5.96594 -1.2902 5.9799
Kapitaludgifter 0 -40.0069 -0.00183 0 0
Udstedelse (Pensionering) af Aktier, Netto 0 102.193 22.7339 11.1475 17.298
Deferred Taxes 0.576
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -14.1197 -3.59365 -33.6407 -25.6499 -16.7863
Cash From Operating Activities -12.6774 -4.82444 -28.3613 -22.0287 -14.3167
Cash From Operating Activities 0.00146 0.00073 0.00292 0.00219 0.00146
Non-Cash Items 2.56255 1.24754 4.46091 3.3344 2.28611
Changes in Working Capital -1.40977 -2.62306 0.23956 0.28456 0.18199
Cash From Financing Activities 0.03127 0 0 0 0
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0.03127 0 0 0
Issuance (Retirement) of Debt, Net 0 0 0
Net Change in Cash -12.6462 -4.82444 -28.3613 -22.0287 -14.3167
Cash From Investing Activities 0 0 0
Capital Expenditures 0 0
Deferred Taxes 0.288 0.144 0.576
Other Investing Cash Flow Items, Total 0
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
Mazur (Leonard L) Individual Investor 6.4557 10255342 -1 2022-11-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8112 6054328 40301 2023-03-31 LOW
Armistice Capital LLC Hedge Fund 1.5265 2425000 -3743361 2021-12-31 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.4586 2317168 4868 2023-03-31 LOW
Holubiak (Myron Z) Individual Investor 1.2541 1992243 0 2022-11-30
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8428 1338777 6154 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3 476597 34000 2023-03-31 LOW
Susquehanna International Group, LLP Investment Advisor 0.2893 459511 130223 2023-03-31 MED
GSA Capital Partners LLP Hedge Fund 0.2849 452561 -46222 2023-03-31 LOW
Renaissance Technologies LLC Hedge Fund 0.2513 399270 -9900 2023-03-31 HIGH
Millennium Management LLC Hedge Fund 0.1917 304482 -246644 2023-03-31 HIGH
Jane Street Capital, L.L.C. Research Firm 0.1549 246023 224990 2023-03-31 HIGH
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1541 244755 7008 2023-03-31 LOW
Hightower Advisors, LLC Investment Advisor 0.1317 209198 14713 2023-03-31 LOW
Inspire Advisors, LLC Investment Advisor 0.125 198632 2686 2023-03-31 LOW
Wealth Advisory Solutions, L.L.C. Investment Advisor 0.0981 155850 0 2023-03-31 MED
AHL Partners LLP Investment Advisor 0.0836 132826 86615 2023-03-31 HIGH
Morgan Stanley & Co. LLC Research Firm 0.0759 120521 31943 2023-03-31 MED
Qube Research & Technologies Ltd Hedge Fund 0.063 100106 -20474 2023-03-31 HIGH
Kestra Advisory Services, LLC Investment Advisor 0.0579 91917 -1800 2023-03-31 MED

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group

535K+

Handlende

87K+

Månedlkige, aktive klienter

$113M+

Månedlig investeringsvolumen

$64M+

Hævet hver måned

Handelslommeregner

Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).

Handelskurtage
0
  • 1:1
Gearing
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long

Citius Pharmaceuticals, Inc. Company profile

Om Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals Inc. er en specialiseret lægemiddelvirksomhed. Virksomheden udvikler og markedsfører produkter til kritisk pleje med fokus på anti-infektive produkter som supplement til kræftbehandling, receptpligtige produkter og mesenchymal stamcelleterapi. Virksomheden har fem produkter: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite og I/ONTAK. Mino-Lok er en antibiotikalås, der anvendes til behandling af patienter med kateterrelaterede blodstrømsinfektioner ved at redde det inficerede kateter. Mino-Wrap er en flydende gelbaseret indpakning til reduktion af vævsekspanderinfektioner efter rekonstruktive brystoperationer. Halo-Lido er en kortikosteroid-lidocain-formulering til lokal anvendelse, som er beregnet til at give antiinflammatorisk og bedøvende lindring til personer, der lider af hæmorider. NoveCite er en behandling med mesenkymale stamceller til behandling af ARDS. I/ONTAK er et manipuleret IL-2 difteritoksin-fusionsprotein til behandling af patienter med persisterende eller tilbagevendende kutant T-celle lymfom.

Industry: Biotechnology & Medical Research (NEC)

11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

Gold

1,948.36 Price
-1.480% 1D Chg, %
Long position, gebyr natten over -0.0185%
Short position, gebyr natten over 0.0103%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.30

XRP/USD

0.52 Price
-1.380% 1D Chg, %
Long position, gebyr natten over -0.0753%
Short position, gebyr natten over 0.0069%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.00394

US100

14,557.80 Price
+0.640% 1D Chg, %
Long position, gebyr natten over -0.0255%
Short position, gebyr natten over 0.0032%
Gebyr natten over, tid 21:00 (UTC)
Spænd 3.0

BTC/USD

27,068.35 Price
-0.530% 1D Chg, %
Long position, gebyr natten over -0.0616%
Short position, gebyr natten over 0.0137%
Gebyr natten over, tid 21:00 (UTC)
Spænd 60.00

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel